flex polyclonal rabbit anti-human cd3 Search Results


96
ATCC antihuman cd3ε
Antihuman Cd3ε, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antihuman cd3ε/product/ATCC
Average 96 stars, based on 1 article reviews
antihuman cd3ε - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

99
Miltenyi Biotec anti human cd3
Anti Human Cd3, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd3/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
anti human cd3 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc rabbit anti–human phospho-erk1/2
Rabbit Anti–Human Phospho Erk1/2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti–human phospho-erk1/2/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
rabbit anti–human phospho-erk1/2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

96
Bio-Rad k rat polyclonal anti human anti cd3
K Rat Polyclonal Anti Human Anti Cd3, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/k rat polyclonal anti human anti cd3/product/Bio-Rad
Average 96 stars, based on 1 article reviews
k rat polyclonal anti human anti cd3 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

90
Agilent technologies polyclonal rabbit anti-human cd3 antibody
Polyclonal Rabbit Anti Human Cd3 Antibody, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal rabbit anti-human cd3 antibody/product/Agilent technologies
Average 90 stars, based on 1 article reviews
polyclonal rabbit anti-human cd3 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Biocare Medical rabbit anti-human cd3 clone ep41
Rabbit Anti Human Cd3 Clone Ep41, supplied by Biocare Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human cd3 clone ep41/product/Biocare Medical
Average 90 stars, based on 1 article reviews
rabbit anti-human cd3 clone ep41 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Agilent technologies rabbit anti-human cd3
Rabbit Anti Human Cd3, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human cd3/product/Agilent technologies
Average 90 stars, based on 1 article reviews
rabbit anti-human cd3 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Thermo Fisher rabbit monoclonal anti-cd3-human antibody clone sp7
Rabbit Monoclonal Anti Cd3 Human Antibody Clone Sp7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit monoclonal anti-cd3-human antibody clone sp7/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
rabbit monoclonal anti-cd3-human antibody clone sp7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

93
Bio-Rad mouse
Mouse, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse/product/Bio-Rad
Average 93 stars, based on 1 article reviews
mouse - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Bio-Rad goat anti rat biotinylated secondary antibody
Goat Anti Rat Biotinylated Secondary Antibody, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti rat biotinylated secondary antibody/product/Bio-Rad
Average 90 stars, based on 1 article reviews
goat anti rat biotinylated secondary antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Agilent technologies rabbit anti-human/mouse cd3
( a ) Representative photographs of mouse tails after surgical excision of superficial/deep collecting lymphatics and treatment with or without topical tacrolimus beginning either 2 weeks (early treatment) or 6 weeks (late treatment) after surgery. Images represent 4 weeks of treatment in the early group and 3 weeks of treatment in the late group. ( b ) Graphical representation of tail volume changes after early (* P =0.021) or late (* P =0.018) treatment with tacrolimus, as compared with controls (red arrows indicate timing of treatment) ( n =8/group). ( c ) Representative cross-sectional histological images (upper panel) of control and early tacrolimus-treated mouse tails harvested 6 weeks after lymphatic ablation. Brackets show soft tissue thickness. Quantification of soft tissue changes (lower panel) after early or late treatment with tacrolimus (* P ≤0.001) ( n =8/group). ( d ) Quantification of whole-blood tacrolimus levels demonstrating immunosuppressive concentrations in systemically treated animals (4 mg kg −1 intraperitoneally daily) and non-immunosuppressive levels in the topically treated group (* P =0.007; n =6/group). ( e ) Representative flow cytometry plots displaying side scatter area (SSA) on the y axis and <t>CD3</t> + cells (T cells) on the x axis for animals retreated with vehicle control, topical tacrolimus or systemic tacrolimus. ( f ) Quantification of blood T cells for each group. Note significant reduction in T cells only in systemically treated animals (* P =0.012; n =6/group). Experiments were repeated two to three times. All data represent mean±s.d. with P ≤0.05 considered as significant. Two-tailed Student's t -test ( c , d ) and analysis of variance (ANOVA) with post hoc tests ( b , f ).
Rabbit Anti Human/Mouse Cd3, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human/mouse cd3/product/Agilent technologies
Average 90 stars, based on 1 article reviews
rabbit anti-human/mouse cd3 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

96
Proteintech 1 ap
( a ) Representative photographs of mouse tails after surgical excision of superficial/deep collecting lymphatics and treatment with or without topical tacrolimus beginning either 2 weeks (early treatment) or 6 weeks (late treatment) after surgery. Images represent 4 weeks of treatment in the early group and 3 weeks of treatment in the late group. ( b ) Graphical representation of tail volume changes after early (* P =0.021) or late (* P =0.018) treatment with tacrolimus, as compared with controls (red arrows indicate timing of treatment) ( n =8/group). ( c ) Representative cross-sectional histological images (upper panel) of control and early tacrolimus-treated mouse tails harvested 6 weeks after lymphatic ablation. Brackets show soft tissue thickness. Quantification of soft tissue changes (lower panel) after early or late treatment with tacrolimus (* P ≤0.001) ( n =8/group). ( d ) Quantification of whole-blood tacrolimus levels demonstrating immunosuppressive concentrations in systemically treated animals (4 mg kg −1 intraperitoneally daily) and non-immunosuppressive levels in the topically treated group (* P =0.007; n =6/group). ( e ) Representative flow cytometry plots displaying side scatter area (SSA) on the y axis and <t>CD3</t> + cells (T cells) on the x axis for animals retreated with vehicle control, topical tacrolimus or systemic tacrolimus. ( f ) Quantification of blood T cells for each group. Note significant reduction in T cells only in systemically treated animals (* P =0.012; n =6/group). Experiments were repeated two to three times. All data represent mean±s.d. with P ≤0.05 considered as significant. Two-tailed Student's t -test ( c , d ) and analysis of variance (ANOVA) with post hoc tests ( b , f ).
1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/1 ap/product/Proteintech
Average 96 stars, based on 1 article reviews
1 ap - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


( a ) Representative photographs of mouse tails after surgical excision of superficial/deep collecting lymphatics and treatment with or without topical tacrolimus beginning either 2 weeks (early treatment) or 6 weeks (late treatment) after surgery. Images represent 4 weeks of treatment in the early group and 3 weeks of treatment in the late group. ( b ) Graphical representation of tail volume changes after early (* P =0.021) or late (* P =0.018) treatment with tacrolimus, as compared with controls (red arrows indicate timing of treatment) ( n =8/group). ( c ) Representative cross-sectional histological images (upper panel) of control and early tacrolimus-treated mouse tails harvested 6 weeks after lymphatic ablation. Brackets show soft tissue thickness. Quantification of soft tissue changes (lower panel) after early or late treatment with tacrolimus (* P ≤0.001) ( n =8/group). ( d ) Quantification of whole-blood tacrolimus levels demonstrating immunosuppressive concentrations in systemically treated animals (4 mg kg −1 intraperitoneally daily) and non-immunosuppressive levels in the topically treated group (* P =0.007; n =6/group). ( e ) Representative flow cytometry plots displaying side scatter area (SSA) on the y axis and CD3 + cells (T cells) on the x axis for animals retreated with vehicle control, topical tacrolimus or systemic tacrolimus. ( f ) Quantification of blood T cells for each group. Note significant reduction in T cells only in systemically treated animals (* P =0.012; n =6/group). Experiments were repeated two to three times. All data represent mean±s.d. with P ≤0.05 considered as significant. Two-tailed Student's t -test ( c , d ) and analysis of variance (ANOVA) with post hoc tests ( b , f ).

Journal: Nature Communications

Article Title: Topical tacrolimus for the treatment of secondary lymphedema

doi: 10.1038/ncomms14345

Figure Lengend Snippet: ( a ) Representative photographs of mouse tails after surgical excision of superficial/deep collecting lymphatics and treatment with or without topical tacrolimus beginning either 2 weeks (early treatment) or 6 weeks (late treatment) after surgery. Images represent 4 weeks of treatment in the early group and 3 weeks of treatment in the late group. ( b ) Graphical representation of tail volume changes after early (* P =0.021) or late (* P =0.018) treatment with tacrolimus, as compared with controls (red arrows indicate timing of treatment) ( n =8/group). ( c ) Representative cross-sectional histological images (upper panel) of control and early tacrolimus-treated mouse tails harvested 6 weeks after lymphatic ablation. Brackets show soft tissue thickness. Quantification of soft tissue changes (lower panel) after early or late treatment with tacrolimus (* P ≤0.001) ( n =8/group). ( d ) Quantification of whole-blood tacrolimus levels demonstrating immunosuppressive concentrations in systemically treated animals (4 mg kg −1 intraperitoneally daily) and non-immunosuppressive levels in the topically treated group (* P =0.007; n =6/group). ( e ) Representative flow cytometry plots displaying side scatter area (SSA) on the y axis and CD3 + cells (T cells) on the x axis for animals retreated with vehicle control, topical tacrolimus or systemic tacrolimus. ( f ) Quantification of blood T cells for each group. Note significant reduction in T cells only in systemically treated animals (* P =0.012; n =6/group). Experiments were repeated two to three times. All data represent mean±s.d. with P ≤0.05 considered as significant. Two-tailed Student's t -test ( c , d ) and analysis of variance (ANOVA) with post hoc tests ( b , f ).

Article Snippet: Rabbit anti-human/mouse CD3 (A0452; 1:300; Dako, Carpinteria, CA) and Cy3-conjugated mouse anti-αSMA (C6-198; 1:1,000; Sigma-Aldrich).

Techniques: Flow Cytometry, Two Tailed Test